Last reviewed · How we verify
Rhinovirus-A16
Rhinovirus-A16 is a Biologic drug developed by Imperial College London. It is currently in Phase 2 development.
Rhinovirus-A16 is a strain of rhinovirus used in clinical trials to study the safety and efficacy of RIG-101, a small molecule intervention, in conditions such as asthma exacerbation and bronchiectasis. The trials involve healthy adult participants and adults with asthma, and the intervention is administered intranasally as a single or repeat ascending dose.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Rhinovirus-A16 |
|---|---|
| Sponsor | Imperial College London |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- RIG 101 Trial in Healthy Adults and Adults With Asthma (PHASE1, PHASE2)
- Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets
- A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rhinovirus-A16 CI brief — competitive landscape report
- Rhinovirus-A16 updates RSS · CI watch RSS
- Imperial College London portfolio CI
Frequently asked questions about Rhinovirus-A16
What is Rhinovirus-A16?
Who makes Rhinovirus-A16?
What development phase is Rhinovirus-A16 in?
Related
- Manufacturer: Imperial College London — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing